

What is claimed is:

1. A drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising one or more unit dosage forms of a first drug and one or more unit dosage forms of a second drug, wherein said first and second drug are independently selected from the group consisting of non-steroidal anti-inflammatory drugs, proton pump inhibitors, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, anti-depressants, selective serotonin reuptake inhibitors, antihistamines, decongestants, biguanides, sulfonylureas, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, anti-epileptic, and anti diabetics.
2. A drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising one or more unit dosage forms of a first drug and one or more unit dosage forms of a second drug, wherein at least one of said first or second drug are selected from the group consisting of non-steroidal anti-inflammatory drugs, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, anti-depressants, selective serotonin reuptake inhibitors, antihistamines, decongestants, biguanides, sulfonylureas, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, anti-epileptic, and anti diabetics.
3. A drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising one or more unit dosage forms of a first drug and one or more unit dosage forms of a second drug, wherein said first and second drug are independently selected from the group consisting of antibiotics and anti-ulcer agents selected from the group consisting of H2 antagonists, antacids, bismuth compounds, prostaglandins, carbenoxolone and anticholinergic agents.

4. The drug packaging system of claim 1 wherein said first comprises a non-steroidal anti-inflammatory drug and said second drug comprises a proton pump inhibitor.

5. The drug packaging system of claim 4 wherein said proton pump inhibitor is omeprazole, lansoprazole, esomeprazole, pantoprazole, isomers, enantiomers or pharmaceutically acceptable salts thereof.

6. The drug packaging system of claim 1 wherein each unit dosage form is independently selected from the group consisting of a tablet, capsule, gel cap, and a caplet.

7. The drug packaging system of claim 4 wherein said non-steroidal anti-inflammatory drug is naproxen, diclofenac, sulindac, oxaprozin, diflunisal, aspirin, piroxicam, indomethacin, etodolac, ibuprofen, fenoprofen, ketoprofen, mefenamic acid, nabumetone, tolmetin, ketorolac, or any pharmaceutically acceptable salt thereof.

8. The drug packaging system of claim 4 wherein said non-steroidal anti-inflammatory drug is diclofenac or a pharmaceutically acceptable salt thereof.

9. The drug packaging system of claim 4 wherein said proton pump inhibitor is omeprazole.

10. The drug packaging system of claim 4 wherein each said unit dosage form is a daily dose for a human patient.

11. The drug packaging system of claim 1 wherein said system is configured as a blister package comprising:

a) a rupturable substrate

b) a layer forming one or more blisters over the rupturable substrate; wherein each of the one or more blisters contain one or more unit dosage forms.

12. The drug packaging system of claim 11 wherein said first drug is a non-steroidal anti-inflammatory drug and said second drug is a proton pump inhibitor.

13. The drug packaging system of claim 11 wherein said proton pump inhibitor is omeprazole.

14. The drug packaging system of claim 11 wherein said non-steroidal anti-inflammatory drug is diclofenac.

15. The drug packaging system of claim 1 wherein said system comprises a plurality of blister packs contained within a single package.

16. The drug packaging system of claim 1 wherein said system comprises unit doses for up to 28 days.

17. The drug packaging system of claim 1 wherein said system comprises unit doses for 7-14 days.

18. The drug packaging system of claim 1 wherein said system comprising one or more dosage forms of a third drug.

19. A method of treating a disease or condition treatable by combined administration of more than one medicament, said method comprising: providing a drug packaging system of comprising one or more unit dosage forms of a first drug and one or more unit dosage forms of a second drug wherein said first and second drug are independently selected from the group consisting of non-steroidal anti-inflammatory drugs, proton pump inhibitors,

calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, anti-depressants, selective serotonin reuptake inhibitors, antihistamines, decongestants, biguanides, sulfonylureas, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, anti-epileptic, and anti diabetics; and  
administering said first drug and said second drug.

20. The method of claim 19 which provides therapy for 1-28 days.